阿根廷卫生部临床试验：伊维菌素对治疗轻度COVID-19的门诊患者显示出益处
这项研究（NCT04784481）
由阿根廷卫生部组织，目的是测试伊维菌素作为替代疗法的功效，该疗法基于药物的再利用作为预防疾病发展的策略。
这项特别的研究
集中于伊维菌素在轻度门诊患者中的使用，以治愈和/或逆转COVID-19疾病的进展，从进展为中度或重度。
以n = 234为目标，受试者
分为实验组（伊维菌素）和对照组。
实验组口服伊维菌素，共7天，共4滴6mg（24mg）滴眼液。
在方案的开始和结束时，所有参与者均通过身体评估进行了评估，并且必须通过RT-PCR对COVID呈阳性。
结论
研究小组的结论是
在患有轻度COVID-19疾病的门诊患者中使用伊维菌素进行治疗可显着减少第5天和第9天的症状数量。
但是，到10天以后，随后的体检并未显示出统计学差异。
伊维菌素在实现医疗释放方面具有显著作用（p = 0.003）。
The treatment with ivermectin
could significantly prevent the evolution to serious stages since the experimental group did not present any patient with referral to critical hospitalization.
In other groups, the patients
did not advance to highest scores in the ordinal scale, which represents more compromised stages of the disease.
Apparently, the Argentinian study group reports that
ivermectin brought other benefits in relation to the improvement in the patient’s condition.
There were no adverse events reported.
Those patients on ivermectin
had a greater than 89.1% probability of being released at the end of the intervention than did the control group (on placebo).
This probability existed even when factoring the presence of comorbidities.
No deaths were recorded in either group of these mild COVID-19 patients.
The median age of study participants (40) as well as comorbidities were equally present in both groups.